Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | August 20, 2018 | August 22, 2018 |
| DEXCOM INCDXCM · Entity 3114 | Director | May 28, 2026 | June 01, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | June 08, 2023 | June 09, 2023 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director · President & CEO | October 06, 2026 | October 07, 2026 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, Chief Financial Officer | November 20, 2018 | November 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.08 · Expires 2028-08-20 | Direct | 25,000 |
Reported balance
After 2018-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-20 · Grant · Acquired 25,000 · Balance 25,000 F1: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period.
DEXCOM INC
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,486 |
Reported balance
After 2026-05-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 5,605 · Balance 12,486 F1: The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2: Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
F2: Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028.
Gossamer Bio, Inc.
Report date June 08, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2033-06-07 | Direct | 35,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 35,000 · Balance 35,000 F1: Award made pursuant to Non-Employee Director Compensation Program. F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award made pursuant to Non-Employee Director Compensation Program.
F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Jazz Pharmaceuticals plc
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 141,394 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 2,000 · Balance 141,394 F1: This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Theravance Biopharma, Inc.
Report date November 20, 2018 · Filed November 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 157,657 |
Reported balance
After 2018-11-20 transaction · row 1
1 source rowRow 1 · 2018-11-20 · Tax withholding · Disposed 6,697 · Balance 157,657 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 7, 2026 21:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,000 | $236.40 | $472,800.00 |
DisclosureSEC source: 0001607737-26-000016 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,394 F1 · kind: This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,000 | $243.03 | $486,060.00 |
DisclosureSEC source: 0001607737-26-000013 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,394 F2 · kind: This transaction was made pursuant to a plan adopted by the reporting person on June 4, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,967 | $246.81 | $485,475.27 |
DisclosureSEC source: 0001607737-26-000013 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,394 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,835 | $237.72 | $1,149,376.20 |
DisclosureSEC source: 0001607737-26-000011 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,361 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GiftOrdinary Shares | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001607737-26-000008 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,196 F1 · kind: Shares were donated to The Gala Family Fund, a donor-advised fund. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 21:34 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000116 · wk-form4_1780349656.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,486 F1 · shares: The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2 · balance_after: Included in this number are 9,418 unvested restricted stock units, 5,605 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 3,813 of which were granted on March 6, 2025 and shall vest through March 6, 2028. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 7,065 | $188.69 | $1,333,094.85 |
DisclosureSEC source: 0001607737-26-000006 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,630 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 44,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001607737-26-000004 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,695 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 5,371 | $171.16 | $919,300.36 |
DisclosureSEC source: 0001607737-26-000002 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,230 F2 · kind: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 00:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001607737-26-000002 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,601 F1 · kind: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 80 | $166.91 | $13,352.80 |
DisclosureSEC source: 0001607737-25-000004 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,860 F1 · balance_after: The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 18,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000074 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,869 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of September, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:09 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000154 · wk-form4_1747080539.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,794 F1 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2 · balance_after: Included in this number are 10,794 unvested restricted stock units, 5,720 of which were granted on March 6, 2025 and shall vest through March 6, 2028 and 5,074 of which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Read SEC document |
| May 08, 2025 Filed Jul 7, 2025 20:15 UTC Amendment | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 1,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000224 · wk-form4a_1751919300.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,881 F1 · shares: The original Form 4, filed on May 12, 2025, is being amended by this Form 4 to correct a calculation error that misreported the number of unvested restricted stock units granted to the reporting person on May 8, 2025. This amendment correctly reports the number of unvested restricted stock units granted to the reporting person on May 8, 2025. F2 · shares: Represents unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. F3 · balance_after: Included in this number are 6,881 unvested restricted stock units, 5,720 of which were granted on March 6, 2025 and shall vest through March 6, 2028 and 1,161 of which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:01 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000055 · wk-form4_1741640507.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,720 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 23:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 5,704 | $138.95 | $792,570.80 |
DisclosureSEC source: 0001765581-25-000025 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,895 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000014 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,599 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 23,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000014 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,044 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,300 | $122.62 | $404,646.00 |
DisclosureSEC source: 0001805688-25-000009 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,933 F2 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001805688-25-000009 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,233 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 80 | $123.45 | $9,876.00 |
DisclosureSEC source: 0001765581-24-000094 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,492 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: The Reporting Person acquired 167 ordinary shares on May 31, 2024 and 48 ordinary shares on November 29, 2024 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 20:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,736 | $115.21 | $200,004.56 |
DisclosureSEC source: 0001765581-24-000040 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,357 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,622 | $117.53 | $425,693.66 |
DisclosureSEC source: 0001765581-24-000036 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,093 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 19,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000015 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,715 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,204 | $119.13 | $381,692.52 |
DisclosureSEC source: 0001784606-24-000006 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,799 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001784606-24-000006 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,003 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 22:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000106 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,887 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of December 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 137 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:15 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001728117-23-000084 · wf-form4_168634174722045.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-07 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 18, 2023 Filed May 20, 2023 00:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,000 | $131.75 | $790,474.20 |
DisclosureSEC source: 0001765581-23-000042 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,978 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.69 to $131.86. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 21:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,807 | $145.78 | $263,424.46 |
DisclosureSEC source: 0001765581-23-000040 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,978 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2023 Filed Mar 8, 2023 02:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,557 | $142.78 | $222,308.46 |
DisclosureSEC source: 0001765581-23-000024 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,785 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 02:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000024 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,342 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,635 | $160.00 | $421,600.00 |
DisclosureSEC source: 0001765581-22-000143 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,558 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 147 annd 51 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively. Read SEC document |
| June 09, 2022 Filed Jul 15, 2022 20:52 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001728117-22-000067 · wf-form4_165791832433011.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-08 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,633 | $162.88 | $265,983.04 |
DisclosureSEC source: 0001765581-22-000038 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,995 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2022 Filed Mar 9, 2022 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 720 | $153.96 | $110,851.20 |
DisclosureSEC source: 0001765581-22-000017 · edgardoc.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,628 F3 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 22:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000017 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,348 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 147 and 124 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28 and November 30, 2021, respectively. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:52 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000061 · wf-form4_162336911267661.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,515 | $164.71 | $249,535.65 |
DisclosureSEC source: 0001765581-21-000050 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,347 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000018 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,862 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:22 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037679 · doc4.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 07, 2020 Filed May 11, 2020 21:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 37,848 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-20-000053 · edgardoc.xml · derivative · entry 3 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,848 Underlying: Ordinary Shares · 37,848 shares Expires 2030-05-06 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 16, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2020 Filed May 11, 2020 21:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 3,652 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-20-000053 · edgardoc.xml · derivative · entry 2 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,652 Underlying: Ordinary Shares · 3,652 shares Expires 2030-05-06 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 16, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2020 Filed May 11, 2020 21:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 16,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000053 · edgardoc.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of April 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:38 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $19.54 | $0.00 |
DisclosureSEC source: 0001209191-19-036222 · doc4.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2029-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 22:42 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,697 | $24.79 | $166,018.63 |
DisclosureSEC source: 0001179110-18-013105 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,657 Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023078 · doc4.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 23:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,695 | $26.95 | $180,430.25 |
DisclosureSEC source: 0001179110-18-010817 · edgar.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,354 Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 1,700 | $27.43 | $46,623.18 |
DisclosureSEC source: 0001179110-18-010637 · edgar.xml · nonDerivative · entry 3 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,049 F3 · price: This transaction was executed in multiple trades at prices from $27.27 to $27.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 39,839 | $26.71 | $1,064,031.96 |
DisclosureSEC source: 0001179110-18-010637 · edgar.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,749 F2 · price: This transaction was executed in multiple trades at prices from $26.265 to $27.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.